FDA approves Selexipag for treatment of pulmonary arterial hypertension
On Dec. 21, the U.S. Food and Drug Administration approved Uptravi (Selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, debilitating,…